U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H4N4O
Molecular Weight 136.1117
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALLOPURINOL

SMILES

c1c2c(ncnc2O)n[nH]1

InChI

InChIKey=OFCNXPDARWKPPY-UHFFFAOYSA-N
InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)

HIDE SMILES / InChI

Molecular Formula C5H4N4O
Molecular Weight 136.1117
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/allopurinol.html | https://www.ncbi.nlm.nih.gov/pubmed/11137320 | http://pubs.acs.org/doi/abs/10.1021/ja01585a023 | https://www.ncbi.nlm.nih.gov/pubmed/16507884

Allopurinol is a xanthine oxidase inhibitor used to decrease high blood uric acid levels. Allopurinol is specifically used to prevent gout, prevent specific types of kidney stones, and for the high uric acid levels that can occur with chemotherapy. Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. Allopurinol is a structural analog of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in man. Allopurinol is metabolized to the corresponding xanthine analog, oxypurinol (Allopurinol), which also is an inhibitor of xanthine oxidase. Allopurinol is taken by mouth or injected into a vein. Common side effects, when used by mouth, include itchiness and rash. Common side effects when used by injection include vomiting and kidney problems.

Originator

Curator's Comment:: http://pubs.acs.org/doi/abs/10.1021/ja01585a023

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.9 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
ZYLOPRIM

Approved Use

INDICATIONS & USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol tablets reduce serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY, CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). Allopurinol tablets are indicated in: -the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). -the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. -the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Launch Date

-1.06358399E11
Secondary
ZYLOPRIM

Approved Use

INDICATIONS & USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol tablets reduce serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY, CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). Allopurinol tablets are indicated in: -the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). -the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. -the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Launch Date

-1.06358399E11
Primary
ZYLOPRIM

Approved Use

INDICATIONS & USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol tablets reduce serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY, CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). Allopurinol tablets are indicated in: -the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). -the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. -the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Launch Date

-1.06358399E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.64 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALLOPURINOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALLOPURINOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.46 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALLOPURINOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALLOPURINOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1544
unhealthy, 52±12
n = 268
Health Status: unhealthy
Condition: Hyperuricemia| Gout
Age Group: 52±12
Sex: M+F
Population Size: 268
Sources: Page: p.1544
Disc. AE: Hypertension, Muscle cramps...
AEs leading to
discontinuation/dose reduction:
Hypertension (1%)
Muscle cramps (0.37%)
Sources: Page: p.1544
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1545
unhealthy, 52±12
n = 268
Health Status: unhealthy
Condition: Hyperuricemia| Gout
Age Group: 52±12
Sex: M+F
Population Size: 268
Sources: Page: p.1545
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.37%)
Sources: Page: p.1545
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2031
unhealthy, 53.4±8.6
n = 54
Health Status: unhealthy
Condition: Gout
Age Group: 53.4±8.6
Sex: M+F
Population Size: 54
Sources: Page: p.2031
Disc. AE: Eosinophilia, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Eosinophilia (1.9%)
Diarrhea (1.9%)
Vomiting (1.9%)
Sources: Page: p.2031
335.7 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 335.7 mg, 1 times / day
Route: oral
Route: multiple
Dose: 335.7 mg, 1 times / day
Sources: Page: p.417
unhealthy, 58.7
n = 83
Health Status: unhealthy
Condition: Chronic gout
Age Group: 58.7
Sex: M+F
Population Size: 83
Sources: Page: p.417
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (2.4%)
Sources: Page: p.417
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 268
Health Status: unhealthy
Condition: Gout
Population Size: 268
Sources:
Other AEs: Upper respiratory tract infections...
Other AEs:
Upper respiratory tract infections (below serious, 52 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Muscle cramps 0.37%
Disc. AE
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1544
unhealthy, 52±12
n = 268
Health Status: unhealthy
Condition: Hyperuricemia| Gout
Age Group: 52±12
Sex: M+F
Population Size: 268
Sources: Page: p.1544
Hypertension 1%
Disc. AE
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1544
unhealthy, 52±12
n = 268
Health Status: unhealthy
Condition: Hyperuricemia| Gout
Age Group: 52±12
Sex: M+F
Population Size: 268
Sources: Page: p.1544
Diarrhea 0.37%
Disc. AE
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1545
unhealthy, 52±12
n = 268
Health Status: unhealthy
Condition: Hyperuricemia| Gout
Age Group: 52±12
Sex: M+F
Population Size: 268
Sources: Page: p.1545
Diarrhea 1.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2031
unhealthy, 53.4±8.6
n = 54
Health Status: unhealthy
Condition: Gout
Age Group: 53.4±8.6
Sex: M+F
Population Size: 54
Sources: Page: p.2031
Eosinophilia 1.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2031
unhealthy, 53.4±8.6
n = 54
Health Status: unhealthy
Condition: Gout
Age Group: 53.4±8.6
Sex: M+F
Population Size: 54
Sources: Page: p.2031
Vomiting 1.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2031
unhealthy, 53.4±8.6
n = 54
Health Status: unhealthy
Condition: Gout
Age Group: 53.4±8.6
Sex: M+F
Population Size: 54
Sources: Page: p.2031
Rash 2.4%
Disc. AE
335.7 mg 1 times / day multiple, oral (mean)
Recommended
Dose: 335.7 mg, 1 times / day
Route: oral
Route: multiple
Dose: 335.7 mg, 1 times / day
Sources: Page: p.417
unhealthy, 58.7
n = 83
Health Status: unhealthy
Condition: Chronic gout
Age Group: 58.7
Sex: M+F
Population Size: 83
Sources: Page: p.417
Upper respiratory tract infections below serious, 52 patients
300 mg 1 times / day steady, oral (max)
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
n = 268
Health Status: unhealthy
Condition: Gout
Population Size: 268
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
no (co-administration study)
Comment: allopurinol in vivo on probes of CYP2C9, CYP2C19 and CYP2D6 metabolism suggest that there are no clinically relevant drug-drug interactions between the drugs metabolized by these enzymes and allopurinol when used concomitantly
no
no (co-administration study)
Comment: allopurinol in vivo on probes of CYP2C9, CYP2C19 and CYP2D6 metabolism suggest that there are no clinically relevant drug-drug interactions between the drugs metabolized by these enzymes and allopurinol when used concomitantly
no
no (co-administration study)
Comment: allopurinol in vivo on probes of CYP2C9, CYP2C19 and CYP2D6 metabolism suggest that there are no clinically relevant drug-drug interactions between the drugs metabolized by these enzymes and allopurinol when used concomitantly
no
no (co-administration study)
Comment: allopurinol in vivo on probes of CYP2C9, CYP2C19 and CYP2D6 metabolism suggest that there are no clinically relevant drug-drug interactions between the drugs metabolized by these enzymes and allopurinol when used concomitantly
no
no (co-administration study)
Comment: allopurinol in vivo on probes of CYP2C9, CYP2C19 and CYP2D6 metabolism suggest that there are no clinically relevant drug-drug interactions between the drugs metabolized by these enzymes and allopurinol when used concomitantly
no
no (co-administration study)
Comment: allopurinol in vivo on probes of CYP2C9, CYP2C19 and CYP2D6 metabolism suggest that there are no clinically relevant drug-drug interactions between the drugs metabolized by these enzymes and allopurinol when used concomitantly
no
no (co-administration study)
Comment: allopurinol in vivo on probes of CYP2C9, CYP2C19 and CYP2D6 metabolism suggest that there are no clinically relevant drug-drug interactions between the drugs metabolized by these enzymes and allopurinol when used concomitantly
PubMed

PubMed

TitleDatePubMed
Rasburicase.
2001
Mannitol treatment in central nervous system lupus.
2001
Guillain-Barré syndrome and allopurinol-induced hypersensitivity.
2001
Flow cytometry analysis of the effect of allopurinol and the dinitroaniline compound (Chloralin) on the viability and proliferation of Leishmania infantum promastigotes.
2001
Sixth international workshop on scleroderma research, Oxford, UK, 30 July--22 August 2000.
2001
Effect of antioxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells.
2001 Apr
Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease.
2001 Apr
Comparison of effectiveness of intracellular and extracellular preservation solution on attenuation in ischemic-reperfusion lung injury in rats.
2001 Apr
Identification of a new point mutation in the human xanthine dehydrogenase gene responsible for a case of classical type I xanthinuria.
2001 Apr
Bioequivalence of allopurinol and its metabolite oxipurinol in two tablet formulations.
2001 Apr
Pharmacoeconomic considerations in the management of acute tumor lysis syndrome.
2001 Apr
Role of intravenous allopurinol in the management of acute tumor lysis syndrome.
2001 Apr
Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia.
2001 Apr
Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
2001 Apr
Photoreactivation of alloxanthine-inhibited xanthine oxidase.
2001 Apr
A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure.
2001 Apr
[The role of ischemic preconditioning in off-pump CABG: is it really necessary to accomplish scrupulous ischemic preconditioning?].
2001 Apr
Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.
2001 Apr 19
Xanthine oxidase-derived reactive oxygen metabolites contribute to liver necrosis: protection by 4-hydroxypyrazolo[3,4-d]pyrimidine.
2001 Apr 30
Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors.
2001 Apr 9
[Therapeutic criteria in hyperuricemia].
2001 Feb
Ornithine carbamoyltransferase deficiency: improved sensitivity of testing for protein tolerance in the diagnosis of heterozygotes.
2001 Feb
Hepatic artery resistance as a marker for preservation/reperfusion injury.
2001 Feb-Mar
Mitochondrial injury limits salvaging marginal livers by machine perfusion.
2001 Feb-Mar
Successful pancreas preservation before islet isolation by the simplified two-layer cold storage method.
2001 Feb-Mar
Celsior is superior to UW for graft preservation from non-heart-beating donors in a canine liver transplantation model.
2001 Feb-Mar
Newly developed cathether set for in situ protection of hearts.
2001 Feb-Mar
[Hypersensitivity to allopurinol. Efficacy of a desensitizing protocol in 3 cases].
2001 Jan
Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest.
2001 Jul
Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients.
2001 Jul-Aug
Accelerated tissue aging and increased oxidative stress in broiler chickens fed allopurinol.
2001 Jun
Cardioprotective effect of propranolol from alcohol-induced heart muscle damage as assessed by plasma cardiac troponin-t.
2001 Jun
An evaluation of the mutagenicity, metabolism, and DNA adduct formation of 5-nitrobenzo[b]naphtho[2,1-d]thiophene.
2001 Jun
Improvement of postpreservation viability of livers from non-heart-beating donors by fibrinolytic preflush with streptokinase upon graft retrieval.
2001 Jun
Type 1 glycogen storage disease and recurrent calcium nephrolithiasis.
2001 Jun
Nitric oxide enhances MPP(+)-induced hydroxyl radical generation via depolarization activated nitric oxide synthase in rat striatum.
2001 Jun 1
The p38 mitogen-activated protein kinase mediates cytoskeletal remodeling in pulmonary microvascular endothelial cells upon intracellular adhesion molecule-1 ligation.
2001 Jun 1
Allopurinol suppresses para-nonylphenol and 1-methyl-4-phenylpyridinium ion (MPP(+))-induced hydroxyl radical generation in rat striatum.
2001 Jun 22
Allopurinol enhances adenine nucleotide levels and improves myocardial function in isolated hypoxic rat heart.
2001 Mar
Ischemia-reperfusion injury after relief of ureteral obstruction: an animal study.
2001 Mar
Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
2001 Mar
Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha.
2001 Mar 22
3-Hydroxyanthranilic acid, an L-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-gamma.
2001 May
C1-inhibitor protects human endothelial cell metabolic activity from prolonged cold storage.
2001 May
Adenine phosphoribosyltransferase deficiency and renal allograft dysfunction.
2001 May
Marked elevation in cortical urate and xanthine oxidoreductase activity in experimental bacterial meningitis.
2001 May 11
Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver: a pilot study in transplant recipients.
2001 May 15
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
2001 May 15
Induction of oxidative stress by humic acid through increasing intracellular iron: a possible mechanism leading to atherothrombotic vascular disorder in blackfoot disease.
2001 May 18
Heart preservation with celsior solution improved by the addition of nitroglycerine.
2001 May 27
Patents

Sample Use Guides

In Vivo Use Guide
The dosage of Allopurinol to accomplish full control of gout and to lower serum uric acid to normal or near-normal levels varies with the severity of the disease. The average is 200 to 300 mg per day for patients with mild gout and 400 to 600 mg per day for those with moderately severe tophaceous gout. The appropriate dosage may be administered in divided doses or as a single equivalent dose with the 300 mg tablet. Dosage requirements in excess of 300 mg should be administered in divided doses. The minimal effective dosage is 100 to 200 mg daily and the maximal recommended dosage is 800 mg daily.
Route of Administration: Other
Primary rat osteoblast cells were obtained from 2-day-old neonatal Sprague-Dawley rats. Following isolation, cells were resuspended in Dulbecco's Modified Essential Medium, supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin (complete mixture abbreviated to DMEM). Cells were cultured for 2–4 days in a humidified atmosphere of 5% CO2–95% air at 37 °C in 75 cm2 flasks until confluent. Upon confluence, cells were sub-cultured into 24- well trays in DMEM supplemented with 2 mM β-glycerophosphate, 50 μg/ml ascorbic acid and 10 nM dexamethasone (supplemented DMEM), with half medium changes every 3 days. Osteoblasts were cultured in the presence of allopurinol and oxypurinol (1 nM–10 mM) to determine the effect on cell proliferation, differentiation, function and gene expression. For the bone formation experiments, cells were also treated with febuxostat and, as a positive control of an anabolic agent, BMP2 (0.1 mM). Unless stated, experiments were carried out at 2 time points during the osteoblast culture; day 7, which represents differentiating osteoblasts, and day 14 (mature, bone forming osteoblasts). All experiments were carefully pH-controlled because bone mineralisation is extremely sensitive to inhibition by acidosis
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:56:15 UTC 2021
Edited
by admin
on Fri Jun 25 20:56:15 UTC 2021
Record UNII
63CZ7GJN5I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALLOPURINOL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
ALLOPURINOL [MART.]
Common Name English
1H-PYRAZOLO(3,4-D)PYRIMIDIN-4-OL
Systematic Name English
ALLOPURINOL [WHO-DD]
Common Name English
ALLOPURINOL [WHO-IP]
Common Name English
ZYLOPRIM
Brand Name English
SUSPENDOL
Common Name English
ALLOPURINOL [JAN]
Common Name English
ALLOPURINOL [INN]
Common Name English
TAKANARUMIN
Common Name English
NSC-101655
Code English
ALLOPURINOL [ORANGE BOOK]
Common Name English
1,5-DIHYDRO-4H-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE
Systematic Name English
BW-56-158
Code English
ALLOPURINOLUM [WHO-IP]
Common Name English
ALLOPURINOL [MI]
Common Name English
ALLOPURINOL [USP-RS]
Common Name English
4H-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE, 1,5-DIHYDRO-
Systematic Name English
ALLOPURINOL [EP]
Common Name English
ALLOPURINOL [HSDB]
Common Name English
DUZALLO COMPONENT ALLOPURINOL
Brand Name English
NSC-1390
Code English
ALLOPURINOL [USAN]
Common Name English
ALLOPURINOL [USP MONOGRAPH]
Common Name English
LOPURIN
Brand Name English
BW 56-158
Code English
ALLOPURINOL [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1637
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
WHO-VATC QM04AA51
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
NCI_THESAURUS C921
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
WHO-VATC QM04AA01
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
LIVERTOX 26
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
WHO-ATC M04AA51
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
WHO-ATC M04AA01
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
NDF-RT N0000000206
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
NDF-RT N0000175698
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 2.3
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
Code System Code Type Description
DRUG CENTRAL
124
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
CAS
184856-42-6
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
SUPERSEDED
IUPHAR
6795
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
LACTMED
Allopurinol
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
NCI_THESAURUS
C224
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
PUBCHEM
135401907
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL1467
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
MERCK INDEX
M1541
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY Merck Index
CAS
39464-14-7
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
SUPERSEDED
RXCUI
519
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY RxNorm
CAS
22767-92-6
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
SUPERSEDED
ECHA (EC/EINECS)
206-250-9
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
WIKIPEDIA
ALLOPURINOL
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
CAS
315-30-0
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
HSDB
3004
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
EVMPD
SUB05338MIG
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
FDA UNII
63CZ7GJN5I
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ALLOPURINOL
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY Description: A white or almost white, microcrystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water and in ethanol (~750 g/l) TS and ether R. Category: Xanthine oxidase inhibitor. Storage: Allopurinol should be kept in a well-closed container. Definition: Allopurinol contains not less than 98.0% and not more than 101.0% of C5H4N4O, calculated with reference to the dried substance.
INN
1731
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
USP_CATALOG
1013002
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY USP-RS
MESH
D000493
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
EPA CompTox
315-30-0
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
DRUG BANK
DB00437
Created by admin on Fri Jun 25 20:56:15 UTC 2021 , Edited by admin on Fri Jun 25 20:56:15 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
In USP/NF not more than 10 ppm of hydrazine is found
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC